Results 21 to 30 of about 34,873 (303)
Bisphosphonate-Linked TrkB Agonist: Cochlea-Targeted Delivery of a Neurotrophic Agent as a Strategy for the Treatment of Hearing Loss [PDF]
, 2018 Hearing loss affects more than two-thirds of the elderly population, and more than 17% of all adults in the U.S. Sensorineural hearing loss related to noise exposure or aging is associated with loss of inner ear sensory hair cells (HCs), cochlear spiral ...
Kim Nguyen (424295) +7 more
core +1 more source
Questionnaire about Occurrence and Condition of Bisphosphonate-Related Osteonecrosis of the Jaw [PDF]
, 2010 The purpose of this study was to survey the occurrence and condition of bisphosphonate-related osteonecrosis of the jaw (BRONJ). A questionnaire inquiring about clinical experience and the condition of patientswith BRONJ was sent to 11 departments of ...
鎌田, 孝広 +2 more
core +1 more source
Can Anti-Tumor Necrosis Factor Agents Be Discontinued in Patients with Inflammatory Bowel Disease?
Gut and Liver, 2021 Background/Aims: Bisphosphonates are increasingly recognized for their anti-neoplastic properties, which are the result of their action on the mevalonate pathway.
Jihye Park, Jae Hee Cheon
doaj +1 more source
Bisphosphonates and Cancer [PDF]
Journal of Veterinary Internal Medicine, 2004 Abstract Bisphosphonates form a family of drugs characterized pharmacologically by their ability to inhibit bone resorption and pharma-cokinetically by similar intestinal absorption, skeletal distribution, and renal elimination. Two groups of bisphosphonates exist chemically, non-amino-bisphosphates and amino-bisphosphonates.
Rowan J, Milner +5 more
openaire +2 more sources
Clinical Case Reports, 2023 Key Clinical Message Chronic use of bisphosphonates, in combination with immunosuppressive therapy, increases the risk of jaw osteonecrosis. When sepsis occurs in patients receiving bisphosphonate, osteonecrosis of the jaw should be considered a ...
Kazuhiko Iwasaki, Akihito Okazaki
doaj +1 more source
Association between bisphosphonate use and COVID-19 related outcomes
eLife, 2023 Background: Although there are several efficacious vaccines against COVID-19, vaccination rates in many regions around the world remain insufficient to prevent continued high disease burden and emergence of viral variants.
Jeffrey Thompson +11 more
doaj +1 more source
Bisphosphonate-Generated ATP-Analogs Inhibit Cell Signaling Pathways [PDF]
, 2018 Bisphosphonates are a major class of drugs used to treat osteoporosis, Paget’s disease, and cancer. They have been proposed to act by inhibiting one or more targets including protein prenylation, the epidermal growth factor receptor, or the adenine ...
Boo Kyung Kim (3077706) +12 more
core +1 more source
Maxillofacial Plastic and Reconstructive Surgery, 2019 Background Botulinum toxin injection on the masticatory muscle induces the osteopenic condition on the ipsilateral condyle. Bisphosphonate suppresses bone resorption and is used to treat osteopenic or osteoporotic condition.
Jae-Young Kim +4 more
doaj +1 more source
Pharmacology of bisphosphonates [PDF]
British Journal of Clinical Pharmacology, 2019 The biological effects of the bisphosphonates (BPs) as inhibitors of calcification and bone resorption were first described in the late 1960s. In the 50 years that have elapsed since then, the BPs have become the leading drugs for the treatment of skeletal disorders characterized by increased bone resorption, including Paget's disease of bone, bone ...
Cremers, S. +4 more
openaire +3 more sources
Gut and Liver, 2021 Background/Aims: Bisphosphonates are increasingly recognized for their anti-neoplastic properties, which are the result of their action on the mevalonate pathway.
Jin Wook Lee, Eun Soo Kim
doaj +1 more source